Interestingly, the levels of Rb1 appear to be correlated with those of glucose transporter 1 (GLUT-1) in BC, suggesting a promising therapeutic approach using GLUT-1 inhibitors in patients with high Rb1 expression [36]. Here, SLC2A1 is linked to breast cancer.